Matthew Woodske, MD
Pulmonary Disease · Beaver, PANPI 1114957990
Payments from drug & device makers
Across 151 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$573
- Johnson & Johnson$499
- Boehringer Ingelheim$301
- AstraZeneca$233
- Insmed, Inc.$139
- Novartis$138
- plus $1K from 27 others
What the payments were for
- Travel & lodging$28610%
- Food & beverage$2,63188%
- Education$873%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 38 | $573 |
| Johnson & Johnson(2 entities) | 11 | $499 |
| Boehringer Ingelheim | 16 | $301 |
| AstraZeneca | 12 | $233 |
| Insmed, Inc. | 8 | $139 |
| Novartis | 6 | $138 |
| Regeneron Healthcare Solutions, Inc. | 5 | $118 |
| Amgen | 5 | $117 |
| Sanofi | 4 | $99 |
| Jazz Pharmaceuticals Inc. | 3 | $87 |
| Philips North America LLC | 4 | $77 |
| Genentech USA, Inc. | 5 | $70 |
| Merck | 4 | $64 |
| Actelion Pharmaceuticals US, Inc. | 3 | $57 |
| United Therapeutics Corporation | 6 | $51 |
| Paratek Pharmaceuticals, Inc. | 2 | $38 |
| Shire North American Group Inc | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Baxter Healthcare | 1 | $31 |
| Inspire Medical Systems, Inc. | 2 | $30 |
| Ambu Inc. | 1 | $28 |
| Grifols USA, LLC | 1 | $24 |
| Mylan Specialty L.p. | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $17 |
| Circassia Inc. | 1 | $16 |
| CSL Behring | 1 | $15 |
| AbbVie | 1 | $14 |
| Gilead | 1 | $14 |
| Biomerieux Inc | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| Fisher & Paykel Healthcare Inc | 1 | $13 |
| Cumberland Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$286
How this compares
$3,003 in reported general payments places this provider in the 60th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 61 | $778,163 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 34 | $527,345 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 510 | $382,498 |
| XolairOmalizumab | 75 | $281,491 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 323 | $170,895 |
| EsbrietPirfenidone | 20 | $161,715 |
| Pirfenidone | 29 | $161,710 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 160 | $111,882 |
| Breo ElliptaFluticasone/Vilanterol | 224 | $103,118 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 133 | $78,709 |
| XareltoRivaroxaban | 79 | $68,178 |
| AdcircaTadalafil | 12 | $49,239 |
| EliquisApixaban | 30 | $34,628 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 70 | $33,696 |
| Spiriva RespimatTiotropium Bromide | 34 | $24,160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $301 | $914,727298 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $573 | $660,7741,070 claims |
| Insmed, Inc.Arikayce | $139 | $527,34534 claims |
| Genentech USA, Inc.Esbriet | $70 | $161,71520 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $233 | $118,561176 claims |
| Johnson & JohnsonXarelto | $499 | $68,17879 claims |
| United Therapeutics CorporationAdcirca | $51 | $49,23912 claims |
| MerckDulera | $64 | $3,94911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Beaver
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
- Tariq CheemaPittsburgh$907K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.